Lenzetto

Estradiol, the active ingredient in Lenzetto, is an estrogen presented as a transdermal patch for transdermal administration. It is indicated for relief of menopausal vasomotor symptoms, correction of estrogen deficiency, and as part of hormone‑replacement therapy to reduce the risk of osteoporosis in postmenopausal women. The product complies with EU regulatory standards and is available by prescription.

GNH USA supplies Lenzetto as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures consistent quality and regulatory compliance across all markets.

Lenzetto provides systemic estrogen through a transdermal delivery system, addressing conditions related to estrogen deficiency.

Menopausal vasomotor symptoms: alleviates hot flashes and night sweats in postmenopausal women. Estrogen deficiency: restores hormonal balance in women with hypoestrogenism. Prevention of osteoporosis: contributes to bone density maintenance to lower fracture risk. Hormone replacement therapy: supports overall estrogen levels as part of comprehensive HRT regimens.

Common Side Effects: - Skin irritation at the patch site: redness, itching or rash where the patch is applied. - Headache: mild to moderate intensity, often transient. - Breast tenderness: discomfort or swelling of breast tissue. - Nausea: occasional upset stomach or feeling of queasiness. - Mood changes: irritability or mild mood swings.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Stroke or transient ischemic attack: neurological symptoms indicating reduced cerebral blood flow. - Myocardial infarction: chest pain or other signs of heart attack. - Endometrial hyperplasia or carcinoma: abnormal uterine bleeding or pelvic pain. - Gallbladder disease: biliary colic or cholecystitis. - Severe hepatic dysfunction: jaundice, elevated liver enzymes.

Before initiating therapy, evaluate individual risk factors and contraindications.

Cardiovascular assessment: screen for history of thromboembolic disease or stroke. Breast cancer screening: perform regular mammography as recommended. Liver function monitoring: assess hepatic enzymes in patients with known liver disease. Pregnancy avoidance: ensure effective contraception, as estrogen can affect fetal development. Contraindication in active thromboembolic disease: do not use in patients with current clotting disorders. Store at room temperature: keep in original pouch, protect from light and moisture.

Estradiol may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce estradiol plasma levels. - CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase estradiol exposure and risk of adverse events. - Anticoagulants (e.g., warfarin): estrogen can enhance anticoagulant effect, increasing bleeding risk.

Moderate Interactions (Monitor Closely): - Thyroid hormone replacement: estradiol may alter thyroid‑binding globulin, affecting hormone levels. - Antidiabetic agents: estrogen can influence glucose metabolism, requiring dose adjustments. - Lithium: monitor serum lithium concentrations, as estrogen may affect renal clearance.